John Petrie

List of Publications by Year in descending order

101 papers	6,864 citations	81900 39 h-index	62596 80 g-index
104 all docs	104 docs citations	104 times ranked	10259 citing authors

#	Article	IF	Citations
1	Female Sex and Angiotensin-Converting Enzyme (ACE) Insertion/Deletion Polymorphism Amplify the Effects of Adiposity on Blood Pressure. Hypertension, 2022, 79, 36-46.	2.7	3
2	Foot Ulcer and Risk of Lower Limb Amputation or Death in People With Diabetes: A National Population-Based Retrospective Cohort Study. Diabetes Care, 2022, 45, 83-91.	8.6	36
3	Knockout of syntaxin-4 in 3T3-L1 adipocytes reveals new insight into GLUT4 trafficking and adiponectin secretion. Journal of Cell Science, 2022, 135, .	2.0	6
4	Prediabetes blunts DPP4 genetic control of postprandial glycaemia and insulin secretion. Diabetologia, 2022, 65, 861-871.	6.3	3
5	Genetic Landscape of the ACE2 Coronavirus Receptor. Circulation, 2022, 145, 1398-1411.	1.6	20
6	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation, 2021, 143, 516-525.	1.6	237
7	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes and Endocrinology,the, 2021, 9, 46-52.	11.4	103
8	Quantitative levels of serum N-glycans in type 1 diabetes and their association with kidney disease. Glycobiology, 2021, 31, 613-623.	2.5	6
9	A post COVIDâ€19 â€˜Marshall Planâ€™ for type 2 diabetes. Diabetic Medicine, 2021, 38, e14439.	2.3	6
10	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes and Endocrinology,the, 2021, 9, 82-93.	11.4	251
11	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. Diabetologia, 2021, 64, 1320-1331.	6.3	19
12	Positioning newer drugs in the management of type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2021, 9, 139-140.	11.4	3
13	Metformin and carotid intimaâ€media thickness in neverâ€smokers with type <scp>1</scp> diabetes: The <scp>REMOVAL</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1371-1378.	4.4	11
14	Time in Range as a Research Outcome Measure. Diabetes Spectrum, 2021, 34, 133-138.	1.0	4
15	Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. CJC Open, 2021, 3, 1257-1272.	1.5	18
16	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. Diabetes Care, 2021, 44, 2010-2017.	8.6	8
17	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care, 2021, 44, 390-398.	8.6	55
18	How tightly controlled do fluctuations in blood glucose levels need to be to reduce the risk of developing complications in people with Type 1 diabetes?. Diabetic Medicine, 2020, 37, 513-521.	2.3	15

#	Article	IF	Citations
19	Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. Diabetologia, 2020, 63, 788-798.	6.3	31
20	Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetologia, 2020, 63, 229-241.	6.3	56
21	Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care, 2020, 43, 250-260.	8.6	175
22	Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. Diabetologia, 2020, 63, 636-647.	6.3	22
23	Metformin and cardiorenal outcomes in diabetes: A reappraisal. Diabetes, Obesity and Metabolism, 2020, 22, 904-915.	4.4	36
24	SGLT2 inhibitors and renal complications in type 1 diabetes. Lancet Diabetes and Endocrinology,the, 2020, 8, 803-805.	11.4	6
25	Time trends in deaths before age 50Âyears in people with type 1 diabetes: a nationwide analysis from Scotland 2004â€“2017. Diabetologia, 2020, 63, 1626-1636.	6.3	6
26	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiologyâ€“Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodiumâ€“Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQq0 0 0 rgBT /Overlock 10	8.6	13
27	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 301-312.	11.4	166
28	Disruption of fasting and post-load glucose homeostasis are largely independent and sustained by distinct and early major beta-cell function defects: a cross-sectional and longitudinal analysis of the Relationship between Insulin Sensitivity and Cardiovascular risk (RISC) study cohort. Metabolism: Clinical and Experimental, 2020, 105, 154185.	3.4	9
29	First among Equals: Macleod, Banting, and the Discovery of Insulin in Toronto. Frontiers in Diabetes, 2020, , 73-83.	0.4	2
30	Longâ€term efficacy and safety of combined insulin and glucagonâ€like peptideâ€1 therapy: Evidence from the LEADER trial. Diabetes, Obesity and Metabolism, 2019, 21, 2450-2458.	4.4	8
31	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. BMC Medicine, 2019, 17, 165.	5.5	43
32	Excess Cardiovascular Risk in Type 1 Diabetes Mellitus. Circulation, 2019, 139, 744-747.	1.6	30
33	Glycaemic control trends in people with type 1 diabetes in Scotland 2004â€“2016. Diabetologia, 2019, 62, 1375-1384.	6.3	45
34	Cardiovascular disease in type 1 diabetes: the elephant in the clinic. Cardiovascular Endocrinology and Metabolism, 2019, 8, 1-2.	1.1	1
35	One hour post-load plasma glucose and 3 year risk of worsening fasting and 2Âhour glucose tolerance in the RISC cohort. Diabetologia, 2019, 62, 544-548.	6.3	10
36	Macrovascular disease: pathogenesis and risk assessment. Medicine, 2019, 47, 65-71.	0.4	2

#	Article	IF	Citations
37	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia, 2019, 62, 621-632.	6.3	33
38	Diabetes and Vascular Disease. , 2019, , 429-437.		0
39	Type 2 diabetes, socioeconomic status and life expectancy in Scotland (2012â€“2014): a population-based observational study. Diabetologia, 2018, 61, 108-116.	6.3	42
40	Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Canadian Journal of Cardiology, 2018, 34, 575-584.	1.7	945
41	N-Glycan Profile and Kidney Disease in Type 1 Diabetes. Diabetes Care, 2018, 41, 79-87.	8.6	75
42	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. Circulation, 2018, 138, 2774-2786.	1.6	139
43	Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. Diabetes Care, 2018, 41, 2010-2018.	8.6	47
44	Renal function markers and insulin sensitivity after 3Âyears in a healthy cohort, the EGIR-RISC study. BMC Nephrology, 2018, 19, 124.	1.8	0
45	Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. Clinical Science, 2018, 132, 1699-1709.	4.3	46
46	Metformin, lipids and atherosclerosis prevention. Current Opinion in Lipidology, 2018, 29, 346-353.	2.7	43
47	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technology Assessment, 2018, 22, 1-64.	2.8	28
48	Expanding The Use Of Glucose Monitoring Technology To Enhance Diabetes Care. , 2018, , .		0
49	Plasma HDL-cholesterol and triglycerides, but not LDL-cholesterol, are associated with insulin secretion in non-diabetic subjects. Metabolism: Clinical and Experimental, 2017, 69, 33-42.	3.4	33
50	Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. Journal of Hypertension, 2017, 35, 493-500.	0.5	57
51	Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. BMC Nephrology, 2017, 18, 163.	1.8	63
52	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 597-609.	11.4	248
53	Fludrocortisone therapy for persistent hyperkalaemia. Diabetic Medicine, 2017, 34, 1005-1008.	2.3	6
54	Metformin in adults with type 1 diabetes: <scp>D</scp>esign and methods of <scp>REducing</scp> with <scp>MetfOrmin V</scp>ascular <scp>A</scp>dverse <scp>L</scp>esions (<scp>REMOVAL</scp>): <scp>A</scp>n international multicentre trial. Diabetes, Obesity and Metabolism, 2017, 19, 509-516.	4.4	32

#	Article	IF	Citations
55	Improving the clinical value and utility of CGM systems: issues and recommendations. Diabetologia, 2017, 60, 2319-2328.	6.3	65
56	Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations. Diabetes Care, 2017, 40, 1614-1621.	8.6	115
57	SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?. Lancet Diabetes and Endocrinology,the, 2017, 5, 841-843.	11.4	9
58	A new perspective on metformin therapy in type 1 diabetes. Diabetologia, 2017, 60, 1594-1600.	6.3	54
59	Identification of novel biomarkers to monitor Î²-cell function and enable early detection of type 2 diabetes risk. PLoS ONE, 2017, 12, e0182932.	2.5	46
60	Cohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO). International Journal of Epidemiology, 2016, 46, dyw152.	1.9	15
61	<scp>LEADER</scp> and the new â€˜cardiovascularâ€™ glucoseâ€lowering agents. Practical Diabetes, 2016, 33, 187-189.	0.3	1
62	LEADER-4. Journal of Hypertension, 2016, 34, 1140-1150.	0.5	13
63	Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetologia, 2016, 59, 2106-2113.	6.3	71
64	Metformin in type 1 diabetes. Practical Diabetes, 2015, 32, 186.	0.3	0
65	Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010. JAMA - Journal of the American Medical Association, 2015, 313, 37.	7.4	454
66	Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia, 2015, 58, 862-870.	6.3	62
67	Insulin Pump Risks and Benefits: A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs. Diabetes Care, 2015, 38, 716-722.	8.6	95
68	Glucose in the coronary care unit. Cardiovascular Endocrinology, 2014, 3, 83-84.	0.8	0
69	Evidence-based estimation of insulin resistance. Diabetologia, 2014, 57, 1743-1745.	6.3	3
70	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrology Dialysis Transplantation, 2014, 29, 1563-1570.	0.7	106
71	Insulin resistance in type 1 diabetes: what is â€˜double diabetesâ€™ and what are the risks?. Diabetologia, 2013, 56, 1462-1470.	6.3	172
72	The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovascular Diabetology, 2013, 12, 130.	6.8	36

#	Article	IF	Citations
73	Longitudinal assessment of endothelial function in the microvasculature of mice in-vivo. Microvascular Research, 2013, 85, 86-92.	2.5	12
74	Euglycemic Clamp Insulin Sensitivity and Longitudinal Systolic Blood Pressure. Hypertension, 2013, 62, 404-409.	2.7	13
75	Ethnic Differences in Glycaemic Control in People with Type 2 Diabetes Mellitus Living in Scotland. PLoS ONE, 2013, 8, e83292.	2.5	30
76	Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage Study. PLoS Medicine, 2012, 9, e1001321.	8.4	270
77	Implications of genome wide association studies for the understanding of type 2 diabetes pathophysiology. Biochemical Pharmacology, 2011, 81, 471-477.	4.4	49
78	Metformin in type 1 diabetes reduces insulin requirements without significantly improving glycaemic control. Reply to Schatz H [letter]. Diabetologia, 2011, 54, 203-204.	6.3	5
79	Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 2011, 54, 2000-2008.	6.3	25
80	What to add in with metformin in type 2 diabetes?. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 185-192.	0.5	12
81	Effect of Socioeconomic Status on Mortality Among People With Type 2 Diabetes: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care, 2011, 34, 1127-1132.	8.6	66
82	The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia, 2010, 53, 809-820.	6.3	175
83	One-Hour Plasma Glucose Identifies Insulin Resistance and Î²-Cell Dysfunction in Individuals With Normal Glucose Tolerance. Diabetes Care, 2010, 33, 2090-2097.	8.6	76
84	Detailed Physiologic Characterization Reveals Diverse Mechanisms for Novel Genetic Loci Regulating Glucose and Insulin Metabolism in Humans. Diabetes, 2010, 59, 1266-1275.	0.6	237
85	Dissecting Insulin Signaling Pathways: Individualised Therapeutic Targets for Diagnosis and Treatment of Insulin Resistant States. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2009, 9, 187-198.	1.2	14
86	Metabolic characteristics of prehypertension: role of classification criteria and gender. Journal of Hypertension, 2009, 27, 2394-2402.	0.5	27
87	Effects of Metformin on Microvascular Function and Exercise Tolerance in Women With Angina and Normal Coronary Arteries. Journal of the American College of Cardiology, 2006, 48, 956-963.	2.8	132
88	Non-esterified fatty acids impair endothelium-dependent vasodilation in rat mesenteric resistance vessels. Clinical Science, 2004, 107, 625-629.	4.3	23
89	Direct Activation of AMP-activated Protein Kinase Stimulates Nitric-oxide Synthesis in Human Aortic Endothelial Cells. Journal of Biological Chemistry, 2003, 278, 31629-31639.	3.4	312
90	Insulin-Stimulated Nitric Oxide Production in Human Aortic Endothelial Cells. Biochemical Society Transactions, 2001, 29, A70-A70.	3.4	0

#	Article	IF	Citations
91	Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clinical Science, 2000, 98, 531-535.	4.3	191
92	Insulin Action Is Associated With Endothelial Function in Hypertension and Type 2 Diabetes. Hypertension, 2000, 35, 507-511.	2.7	109
93	Pioglitazone. Drugs, 2000, 60, 344-345.	10.9	1
94	INSULIN AS A VASCULAR HORMONE: IMPLICATIONS FOR THE PATHOPHYSIOLOGY OF CARDIOVASCULAR DISEASE. Clinical and Experimental Pharmacology and Physiology, 1998, 25, 175-184.	1.9	88
95	Dietary Sodium Restriction Impairs Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1552-1557.	3.6	58
96	Insulin-sensitising agents. Expert Opinion on Emerging Drugs, 1998, 3, 247-260.	1.1	8
97	Specific insulin assays, insulin sensitivity and blood pressure. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 465-475.	0.5	5
98	THE EUGLYCAEMIC HYPERINSULINAEMIC CLAMP: AN EVALUATION OF CURRENT METHODOLOGY. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 513-518.	1.9	37
99	Endothelial Nitric Oxide Production and Insulin Sensitivity. Circulation, 1996, 93, 1331-1333.	1.6	254
100	New Pharmacological Approaches to Insulin and Lipid Metabolism. Drugs, 1994, 47, 701-710.	10.9	14
101	Quality of life in people with Type 2 diabetes; a study in a multi-ethnic clinical trial population. British Journal of Diabetes, 0, , .	0.2	0